CardioHealth Alliance welcomed Novo Nordisk Inc. to the CardioHealth Alliance group on March 9, 2023, aiming to expedite evidence-based solutions for prevention and care of cardiovascular, renal and metabolic cardio-metabolic diseases.
The CardioHealth Alliance brings together a multi-disciplinary group of experts to improve the care and health of patients across cardiovascular, renal, and metabolic diseases. The alliance, which was established by leaders from the Duke Clinical Research Institute (DCRI) and the Stanford Center for Clinical Research, welcomed Novo Nordisk Inc. as a new member and invited its clinicians, patients, data scientists, health care leaders, and policy makers to partner to improve disease care pathways and expedite the implementation of evidence into practice.
The new partnership makes Novo Nordisk Inc. the third pharmaceutical company to join the alliance in 2023 and the sixth overall following the announcement that Boehringer Ingelheim and Eli Lilly and Company joined last month.
“The CardioHealth Alliance is focused on taking new approaches to the clinical study and implementation of heart health care,” said Ken Mahaffey, MD, Professor of Cardiovascular Medicine at Stanford University School of Medicine and director of the Stanford Center for Clinical Research. “We’re also addressing the value of care through policy. Together, we are focused on disrupting how we prevent and care for this pervasive disease, which costs substantial loss of life, as well as billions of dollars each year in health care.”
The alliance will continue to leverage existing partnerships with large health systems and other research institutions, including Novo Nordisk Inc., to manage a broad portfolio of research.
The alliance’s key goals are to:
- Use real-world data to inform real-world care
- Develop and test new pathways and practices
- Scale and optimize best practices
- Continuously address value of care through effective policy
The collaboration aims to address some of the world’s biggest public health concerns by helping evidence-based therapies become integrated into real-world clinical practice.
“Heart disease remains the leading cause of death in the U.S.,” said Adrian Hernandez, MD, MHS, cardiologist and executive director of the DCRI. “We need a collaborative, multi-disciplinary approach to rapidly advance new ways to study the disease and streamlined paths to apply what we learn. Harnessing the collective experience of stakeholders will result in better solutions that are based in data and implemented more quickly for the patients who need it most.
For more information, visit cardiohealthalliance.org or contact CardioHealthAlliance@dm.duke.edu.
About the Duke Clinical Research Institute (DCRI)
The DCRI, part of the Duke University School of Medicine, is the largest academic clinical research organization in the world. Our mission is to develop, share, and implement knowledge that improves global health through innovative clinical research. The institute conducts multinational clinical trials, manages major national patient registries, and performs landmark outcomes research. The DCRI is a pioneer in cardiovascular clinical research, and conducts groundbreaking clinical research across multiple other therapeutic areas, including infectious disease, neuroscience, respiratory medicine, and nephrology. The DCRI serves as the coordinating center for PCORnet®, The National Patient-Centered Clinical Research Network.
About the Stanford Center for Clinical Research (SCCR)
SCCR is an Academic Research Organization (ARO) within the Department of Medicine in the Stanford University School of Medicine. The mission of SCCR is to advance impactful clinical research through quality operations. The SCCR leverages physical and intellectual resources of Stanford University and its affiliated teaching hospitals and research centers to achieve this mission. In collaboration with faculty and sponsors, SCCR conducts innovative and evidence-based operations and has particular expertise in evaluation of mobile and digital technologies.